Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
July 30, 2026
Earnings Call Speaker Segments
Morgan Sanford
executiveThanks, operator. Hello, everyone, and good morning. We appreciate you being here as we go over Agios Pharmaceuticals' business highlights and financial results for the second quarter of 2026. Today's call slides can be found in the investors section of our website, agios.com. I want to remind you that certain forward-looking statements will be made today. Because of a range of risks, uncertainties, and other factors — including those described in our most recent SEC filings and any future filings we may make with the SEC — actual events and results may differ materially from what any forward-looking statements express or imply. Joining me on today's call from Agios are Brian Goff, our Chief Executive Officer; Cecilia Jones, our Chief Financial Officer; Tsveta Milanova, our Chief Commercial Officer; and Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development. Once prepared remarks are done, we'll open the call for questions; with that, it's my pleasure to hand things over to Brian.
Brian Goff
executiveThanks, Morgan, and good morning to all of you — we appreciate you being here. Ahead of walking through our second quarter results, I want to pull back for a moment and point to the solid footing Agios stands on as we keep pushing toward our aim of creating a rare disease business worth multiple billions of dollars; we're driving forward on several sources of value, among them the AQVESME launch in thalassemia, the chance to broaden mitapivat into sickle cell disease, and a pipeline growing via internal innovation as well as disciplined business development. This quarter we bolstered our portfolio further by bringing in cevidoplenib, an oral Syk inhibitor that is next-generation and highly selective, which stretches our rare hematology franchise into immune thrombocytopenia, or ITP. We moved AG-236 as well into an operationally seamless Phase II/III program for polycythemia vera, adding yet another possible growth driver in hematology. Outside of hematology, AG-181 keeps moving forward. For phenylketonuria patients, we anticipate phase I-B proof of mechanism data during the year's second half. We likewise maintain a disciplined stance on managing the portfolio, making targeted investment choices, and steering resources to the opportunities best able to generate value for patients and shareholders. As will become clear during today's call, what we achieved this quarter shows how strong that strategy is, blending commercial execution, pipeline advancement, disciplined capital allocation, and strategic business development so that Agios is positioned for sustainable long-term growth. Moving to our second quarter highlights on the following slide, we turned in a quarter defined by robust commercial performance, significant pipeline progress, and ongoing portfolio discipline. To begin, we produced sustained commercial momentum, with $44.7 million in total net revenue, which included $40.9 million in the U.S. and 442 cumulative AQVESME prescriptions written by REMS-certified physicians. Next, we broadened our pipeline further by in-licensing cevidoplenib, a next-generation, highly selective oral Syk inhibitor for ITP, which is moving toward phase III and makes our rare hematology pipeline stronger. Third, we moved mitapivat ahead toward a possible new indication in sickle cell disease. This quarter, the FDA accepted our sNDA with priority review and gave us a PDUFA goal date of November 1st, which puts us one step nearer to providing a first-in-class medicine in an area with substantial unmet need. Last, we closed the quarter holding roughly $1 billion in cash equivalents, and marketable securities, which gives us financial flexibility to back both commercial growth and pipeline progression. All in all, we began the second half of 2026 with robust commercial delivery, a more diversified pipeline, a key near-term regulatory catalyst, and the capital position needed to carry out our strategy. With that, please go to the next slide. I'll hand the call to Cecilia to cover financials.
Cecilia Jones
executiveThanks, Brian. Let's move to the next slide. Now for our Q2 financial results: total mitapivat net revenue came in at $44.7 million, which breaks down as $40.9 million within the U.S. and $3.8 million from outside the U.S. Cost of sales during the quarter stood at $3 million. R&D expense reached $100.8 million, versus $91.9 million in Q2 of 2025, largely driven by a $15 million rise in process research and development tied to the $25 million upfront payment connected to the Oscotec agreement. SG&A expense totaled $61.5 million, up against $45.9 million in the same period last year, which reflects more commercial-related activity as we carried out the AQVESME launch in February. Our net loss for Q2 of 2026 was $100.7 million, compared with a net loss of $112 million in Q2 of 2025. We closed the quarter holding roughly $1 billion across cash equivalents and marketable securities, which in our view gives us the financial flexibility to back commercial execution, move our pipeline forward, and keep investing in opportunities that build long-term value. Now on our 2026 outlook: we still anticipate somewhere around $45 million-$50 million in PK deficiency revenues from the U.S. For the full year, operating expenses should stay roughly level against 2025, once you exclude the $25 million upfront payment tied to the cevidoplenib licensing transaction that was recognized in Q2, and that figure includes investment to get ready for a possible sickle cell disease launch in line with our November 1st PDUFA date. Our priorities for the rest of the year haven't changed: push the AQVESME launch, get ready for a possible sickle cell disease approval, move our pipeline ahead, and stay financially disciplined. Please go to the next slide, and I'll hand things to Tsveta for commercial highlights and an update on the AQVESME U.S. thalassemia launch.
Tsveta Milanova
executiveThank you, Cecilia. Let's move to the next slide; now that we have 6 months of launch experience under our belts, the fundamental drivers behind our performance give us reason for optimism. Everything we've observed up to this point keeps bolstering our belief in the long-term PYRUKYND opportunity within thalassemia. Notably, the robust execution demonstrated throughout our commercial and patient-focused teams makes us even more confident about upcoming launch opportunities. Within the U.S., results showed ongoing expansion in thalassemia demand along with dependable commercial execution. Net revenue for the quarter included roughly $5 million in one-time benefits tied to stocking in thalassemia, plus modest gross-to-net favorability. Our expectation remains that gross to net will fall inside the 10%-20% range we previously guided, with variability from quarter to quarter. Beyond the U.S., we achieved $3.8 million in net sales, which mirrors expected thalassemia demand in Europe now that approval has occurred, as well as steady, consistent early thalassemia demand in the GCC. As we've consistently observed throughout rare disease launches, the pattern of new patient starts naturally levels off as adoption extends past the initial group of highly motivated patients and prescribers. Our expectation for quarter-over-quarter revenue variability remains, driven by order timing, inventory movement, and gross-to-net dynamics. Let's go to the next slide, please. I'm extremely pleased with how the U.S. launch of PYRUKYND has continued to perform. In the second quarter, we produced 200 additional prescriptions from REMS-certified physicians, which lifted cumulative prescriptions to 442 as of June 30th. As a reminder, this metric tracks unique prescriptions for patients with completed START forms from REMS-certified physicians and acts as an early signal of underlying demand. Crucially, the launch dynamics beneath the surface stay healthy. Demand keeps arriving from highly motivated patients. We observed a rising share of non-transfusion-dependent patients during the second quarter, a profile that aligns with the therapy advancing past the earliest, most motivated cohort of transfusion-dependent patients. Strong conversion from prescription to treatment initiation remains evident. Time to START is naturally moving toward the 10 to 12-week range we anticipated as adoption widens across the NTDT population, where treatment decisions frequently require more deliberate clinical discussions and patients might interact with the healthcare system less often. Access keeps getting stronger. We currently have roughly 75% of thalassemia lives covered through payer policies. On top of that, physician REMS certification keeps advancing in step with prescribing activity. It does not stand as a barrier to patient access. As the launch progresses, prescriptions with completed START forms become a less useful performance measure. Revenue, by contrast, increasingly captures both new patient starts and persistence on therapy. Because of that, in anticipation of a possible FDA approval for mitapivat in sickle cell disease, we intend to stop reporting prescriptions from REMS-certified physicians following the third quarter and shift to revenue as our main commercial performance measure. If sickle cell disease approval occurs, we will evaluate which metrics best convey the progress and outlook of the wider mitapivat franchise. Let's move to the next slide, please. I'd like to spend a few moments highlighting thalassemia launch considerations for the second half of this year. The first six months represented a clear early stage of the rollout. During the initial quarter, we gained from substantial anticipation before launch and momentum that accumulated in the stretch prior to approval, which came after the PDUFA delay exceeding three months. Demand in the second quarter keeps showing uptake among patients and prescribers who are highly motivated, and the time to starting treatment is starting to get close to the 10 to 12-week average we anticipated once the launch reaches maturity. Going forward, we anticipate the launch's shape will evolve in a natural way. Adoption is broadening into a larger non-transfusion-dependent group, in which patients generally are seen less often and choices about treatment can require additional time. As the mix of patients keeps moving toward those who are non-transfusion-dependent, we anticipate that time to treatment initiation will land well inside the 10 to 12-week range we regularly reference; we also keep in mind that the earliest group of patients who began therapy in the launch's first month is nearing six months of treatment, which is a natural moment for physicians to evaluate clinical response. This represents a key portion of the treatment journey. During this stretch, we will start developing a wider real-world understanding of the way physicians and patients assess response and bring mitapivat into long-term care. All together, these dynamics confirm that AQVESME is producing a healthy launch that is moving successfully past the initial wave of adoption and into a wider expansion phase. As we progress through the latter half of the first launch year, we stay focused on broadening reach throughout the thalassemia community, growing adoption in the non-transfusion-dependent segment, and continuing to bring on new prescribers. We stay very confident in the long-term opportunity for AQVESME and in our capacity to build a durable, growing thalassemia franchise as time goes on. Please advance to the next slide. We are actively getting ready for a possible sickle cell disease launch in the U.S; and we are encouraged by both the commercial opportunity and the unmet need that we observe in this community. Our initial launch focus centers on roughly 25,000 patients who are actively treated or in need of therapy today. We think this population by itself offers a meaningful opportunity for mitapivat, with room to grow beyond the initial segment as time goes on. Importantly, we are drawing on the capabilities, relationships, and insights we have built through the thalassemia launch while we keep investing in market access, education, and community engagement activities ahead of the PDUFA goal date. If FDA approval comes, we think these efforts put us in a good position to support a successful launch and to deliver mitapivat to patients who need innovative treatment options. Please advance to the next slide. With that, I will turn the call over to Sarah to cover key R&D highlights from the quarter.
Sarah Gheuens
executiveThanks, Tsveta. Now let's look at our pipeline on the following slide. After recent decisions to prioritize the portfolio, our focus stays on moving forward a diversified rare hematology pipeline, with opportunities spanning several stages of development. Mitapivat remains the anchor of that portfolio, with approved indications in pyruvate kinase deficiency and thalassemia, plus a possible accelerated approval in sickle cell disease later in the year. In the first half of this year, we hit a significant milestone when thalassemia was approved in Europe and the UAE, which completed regulatory approvals in all four priority launch geographies, after earlier approvals in the U.S. and KSA. Since the first quarter results, we submitted and gained acceptance in the U.S. for the mitapivat sNDA in sickle cell disease, with priority review and a PDUFA goal date of November 1st. We stay dedicated to getting mitapivat to sickle cell disease patients, and we recently dosed the first patient in reignite, our phase III confirmatory trial — a key milestone in moving the program forward. We also bolstered the pipeline in the quarter by in-licensing cevidoplenib, a next-generation Syk inhibitor that widens our footprint in rare hematology and brings in a compelling opportunity in immune thrombocytopenia. In addition to mitapivat and cevidoplenib, we keep investing in future growth drivers, such as AG-236 in polycythemia vera and AG-181 in phenylketonuria. All told, we believe the pipeline shows a focused use of capital and resources on programs where we see the biggest chance to build long-term value for patients and shareholders. Please go to the next slide. As we said when we announced the in-licensing of cevidoplenib, our interest in this program rests on its potential to tackle some of the limitations that have historically held back the Syk inhibitor class. Cevidoplenib was engineered to optimize both selectivity and pharmacokinetics, to support sustained target inhibition while keeping a tolerability profile appropriate for chronic use. The clinical data produced so far are encouraging and back up this design rationale, showing dose-dependent activity, no dose-limiting toxicity through phase II, and evidence of durable platelet responses. All together, these data support the rationale for moving cevidoplenib forward as a next-generation highly selective Syk inhibitor. We look forward to engaging with the FDA in the months ahead to align on progression to phase III. Next slide, please. At EHA in June, we were glad to share a broad set of data across both thalassemia and sickle cell disease that keeps strengthening our confidence in mitapivat. Across the portfolio, 10 abstracts were accepted, including the RISE UP phase III study, which was chosen for the EHA oral plenary session. In sickle cell disease, RISE UP showed hemoglobin responses consistent with the mechanism of PK activation, with hemoglobin responders seeing clinically meaningful improvement in sickle cell pain crisis-related endpoints and fatigue. At EHA, we presented new data showing clinically meaningful reductions in transfusion burden and red blood cell units transfused across the total trial population, exceeding historical experience with hydroxyurea. What mattered greatly were the results seen among the subgroup of patients who had received at least one transfusion during the 52 weeks before joining the study. Those findings went on to shape the assumptions around treatment effect and statistical power for REIGNITE, our confirmatory trial that is still running, and they backed the accelerated approval. We also shared extra patient-reported outcomes data demonstrating meaningful clinical gains in the way hemoglobin responders feel and function, among them less physical pain. Beyond that, 56-week follow-up results from SATISFY, a phase II investigator-sponsored study in related hemoglobinopathies, reveal strong rates of hemoglobin response along with average hemoglobin improvement, and they hint at a reduced iron burden. When it comes to non-transfusion-dependent thalassemia, we presented open-label extension findings in which 60% of patients who stayed on mitapivat met hemoglobin response criteria, while 60% of those who moved over to mitapivat during the open-label extension also achieved a hemoglobin response. On top of that, subgroup analyses point to high hemoglobin response rates among non-transfusion-dependent patients whose baseline hemoglobin levels were high, which tells us that less severely anemic NTDT patients do see gains in hemoglobin levels and in fatigue. The thalassemia community responded to this data very positively, and it underscores mitapivat's value in non-transfusion-dependent patients, who make up most of the eligible adults in the U.S. All of this together reinforces how consistent mitapivat's profile is across indications and makes us even more confident about mitapivat's long-term potential in hemolytic anemia. As we keep pushing forward and broadening the mitapivat opportunity, our attention is likewise on constructing the next generation of possible growth drivers in rare hematology. AG-236 stands as a key illustration of that approach. Let's go to the next slide, please. After promising phase I data, we are moving AG-236 ahead into a phase II/III development program in polycythemia vera that is operationally seamless. What keeps setting AG-236 apart is the profile it may offer within a treatment landscape that keeps changing. This molecule showed hepcidin induction out through day 57 as well as favorable impacts on iron parameters in extended follow-up, which supports the possibility of a dosing regimen given every six months without saturation. The phase II part of this study is built to pinpoint the optimal therapeutic window across several dose levels, all while allowing efficient movement into the registrational portion of the program. More broadly, this seamless phase II/III approach speaks to our dedication to disciplined execution while pushing development forward as efficiently as we can, with phase II set to begin in the second half of 2026. We think AG-236 may further diversify our rare hematology leadership and add to our long-term growth beyond mitapivat. With that, please advance to the next slide, and I will give the call back to Brian for closing remarks.
Brian Goff
executiveThanks, Sarah. Let's bring up the following slide. Looking across the entire company, we continue to make good headway against the strategic goals we laid out for 2026. Commercially, AQVESME and thalassemia are building momentum, with 442 prescriptions in total as of June 30th. Beyond that, mitapivat is advancing toward a potential approval in sickle cell disease — a major opportunity to expand our PK activation franchise and a possible next growth driver for the business. We're also moving AG-236, our siRNA TMPRSS6 inhibitor aimed at polycythemia vera, into a phase II/III program designed to run operationally seamlessly, which ought to get underway in the back half of this year. In the quarter, we added cevidoplenib as a further move toward a more varied portfolio. It's a next-generation Syk inhibitor that is highly selective, targets ITP, and is moving toward phase III. What matters here is that this year's results demonstrate both discipline and execution. We are directing investment toward the opportunities where Agios, in our view, can have the greatest impact on patients and create the most durable long-term value for shareholders. Moving to the next slide. Taking everything together, as we enter the second half of the year, we have a commercial base that continues to expand, a significant regulatory catalyst coming up in the near term, a pipeline that is becoming more diversified, and the financial strength needed to execute our strategy. Next slide, please. At this point, Agios is built on a commercial operation that keeps expanding, and behind it sits a pipeline reaching across several stages of development and multiple disease areas. Across that portfolio, we're pursuing chances where distinctive biology, substantial unmet needs among patients, and execution carried out with discipline can support growth that lasts over the long term. Combined, these chances add up to rare disease markets projected to exceed $10 billion in 2030. Before we take questions on the call, I'd like to express appreciation to everyone at Agios for their steadfast commitment to patients and their ongoing dedication to carrying out our strategy. Their passion, resilience, and focus have been instrumental in the progress we've made this year. With that, thank you all for joining us today. Operator, let's open it up for questions now.
Alec Stranahan
analystHello there. Hey, everyone. I appreciate you fielding my questions. Nice work on the very solid quarter. I've got two things to ask. First, regarding duration of therapy in the commercial setting, would you consider the ENERGIZE trials a reliable gauge for this? I'm just attempting to work out how the possibility of patients discontinuing their treatment might affect sales in the back half. In terms of time on treatment, was there any shift from 1Q to 2Q? Did it get nearer to or farther from that 10 to 12 week average range you've been describing? Also, I suppose, are you beginning to observe any repeat prescriptions within the REMS program yet? Thanks.
Brian Goff
executiveThank you, Alec. A two-part question. Tsveta, please handle the first one. In fact, you'll handle both of them.
Tsveta Milanova
executiveYes.
Brian Goff
executiveRegarding how long patients stay on therapy, with ENERGIZE as a comparison — the second item, Alec, I believe what you're actually asking about isn't duration on treatment but rather the wait before starting it, meaning the gap between demand and initiation. Tsveta, would you like to address that?
Tsveta Milanova
executiveSure. We're really happy with how strongly AQVESME has performed out of the gate, Alec. Like we said, across the launch's first 2 quarters, we've got 442 prescriptions in total from physicians certified through REMS. Looking forward, during those initial couple of quarters, our time to treatment initiation came in faster than we'd expected. It beat the 10 to 12 weeks, since the prescriptions we're getting come from patients and physicians who are highly motivated. With that in mind, we'll soon hit the natural six-month mark, when both physicians and patients assess how much benefit the product delivers along with continuation rates. That lands more in the year's second half, and we'll keep a close watch on it. Right now, what the market shows us is very strong feedback, and the feedback from the community is positive. We anticipate continuation rates matching the ENERGIZE study; we'll keep monitoring that, but the product's performance in the market is very strong. On time to treatment initiation, we're beginning to see that as we penetrate the entity settings, it moves nearer and nearer to what we originally anticipated, the 10 to 12-week range. As we head into the year's second half, we'll keep monitoring that, but given how strongly we've penetrated the entity settings, we expect to land well within the 10 to 12 weeks. Your third question concerned repeat prescriptions for the REMS. Looking at that, naturally, we have patients who've been on therapy for multiple months; we are starting to see repeat prescriptions, and patients and physicians are moving through the REMS process very, very smoothly.
Alec Stranahan
analystGood. Thank you.
Andrew Berens
analystHi there. Thanks, and nice work on the strong execution. I'd like to dig a bit deeper into the persistence rate, given how much it matters down the road. Can you share anything about the expanded access program, perhaps? What will these patients' experience look like in the real world? Another thing that's clearly quite important is the sickle cell label — whether it ends up on AQVESME or PYRUKYND. What factors will play into that? Andy, with the November 1st PDUFA still ahead of us, is there anything at this early stage that could reassure us that AQVESME won't face a REMS requirement or need a price cut in thalassemia? Thanks.
Brian Goff
executiveThanks, Andy. Once more I'll say — and I appreciate what you said about the solid quarter — the ongoing execution by Tsveta and the team makes me genuinely pleased and proud. Regarding persistence, Andy, perhaps Sarah should kick things off by sharing her thoughts on the clinical trial and the open label extensions — what we observed there. It's still too soon for us to put a number on how long patients stay on treatment, but we've consistently treated those studies and OLEs as a stand-in.
Sarah Gheuens
executiveAbsolutely. Thank you, Brian. Andy, I believe what we have here is the opportunity to examine the open-label findings that we shared at EHA not long ago. As you're aware, the continuation rates are extremely high among individuals who complete the clinical trials and subsequently enter the open-label extension; at this point, we're fortunate to have been able to track them over a stretch of time following the randomized control trial, and what that shows is that response is maintained well. People stay on the therapy. You observe hemoglobin staying stable, the anti-hemolytic response being sustained, and patients reporting they feel well. One more thing worth noting — something that was quite encouraging in the EHA dataset — was that those with elevated hemoglobin levels also responded favorably to the treatment, which matters a great deal, naturally, as we keep broadening the population we reach in the launch for non-transfusion dependent patients. Right, I'd say the clinical trial data is genuinely the optimal lens through which to consider that question at this moment. Yes.
Tsveta Milanova
executiveYes. To wrap up, I've devoted considerable time to working alongside clinicians in the field, and I had the chance to hear what they had to say regarding the EHA data. With us moving into the year's second half, and as real-world assessment of persistency begins to take shape, I have strong confidence that we will witness a repeat of what the clinical trials show when it comes to continuation rates at 6 months.
Sarah Gheuens
executiveAnd then when it comes to—
Andrew Berens
analystCould you provide us—
Sarah Gheuens
executiveOh, my apologies.
Andrew Berens
analystLet me just ask this — could you provide a figure, a percentage, from the open label extension study regarding patients who remained on treatment?
Sarah Gheuens
executiveIn ENERGIZE, continuation from the clinical trial exceeded 90%. Yeah, and then naturally, as time goes on, clinical trials are burdensome, so it declines somewhat, but persistence is very good, whether for PKD, thalassemia, or sickle cell disease in the clinical trials. What stood out there is also the response rate with longer exposure, which matters for thalassemia — from the early 40%, some non-responders converted into responders. We reached a 60% response rate there. The clinical trial data is very good.
Brian Goff
executiveClearly, we recognize that metric matters a great deal to us moving ahead. It's still quite early — this marks only our second complete quarter since launch, which roughly corresponds to how long the ENERGIZE trial ran. We'll keep watching it closely and, naturally, put the right patient services support in place so patients stay on therapy. Andy, could you please restate the latter portion of your question?
Andrew Berens
analystYeah. Clearly, nobody really thinks pricing for sickle cell will hold up the way it does for thalassemia or PKD. It truly hinges on whether a sickle cell indication gets added to Exjade or to PYRUKYND. What do you believe will be the deciding factor there, and do you have any thoughts, given that we're just a few months out from the PDUFA, on which of those brands sickle cell could be added to if it gets approved?
Sarah Gheuens
executiveYeah. The PDUFA date is November 1st, priority review; that has us really excited. We haven't had any further talks about which brand name will be chosen, but as you're aware, the data from the clinical trial came out looking very strong. We didn't see the hepatocellular injury that showed up in the sickle cell disease patients. So a REMS may not be needed. Regardless, our teams stand ready to carry out a launch whether or not a REMS is in place. Stay tuned for more.
Tsveta Milanova
executiveDefinitely.
Andrew Berens
analystAll right.
Tsveta Milanova
executiveWhen we get to launch and have the label in hand, we'll share further details as we always do; for that indication and throughout the portfolio, we'll set the price so as to make the most of the opportunity, taking into account the clinical data, naturally, and the market conditions at that point. Given that this is our third indication, I have to say our position is quite strong. In sickle cell disease, unmet need is extremely high. Our market access team is very strong. The progress they achieved with payer policies in thalassemia makes me very proud; from here, we'll keep learning and building.
Andrew Berens
analystExcellent. I appreciate you taking the questions. Congratulations once more on the robust quarter. It appears that this momentum is set to carry on.
Brian Goff
executiveThank you, Andy.
Analyst
analystHey, everyone. Supath here, filling in for Greg. Congratulations. Let me also pass along my congrats to the whole team on a fantastic quarter. If I can, I have a question with two parts. Once we get into the back half of 2026 and pass the first group of highly motivated transfusion-dependent patients, how should we frame the run rate for new patient starts, especially across the wider non-transfusion dependent population? Part two is, where do you stand on gross? I realize it's favorable this quarter. Within that 10%-20% expected target range, where are you? Right now you're at 75% of cover life. Thanks, and congrats once more.
Brian Goff
executiveThanks, Supath. Tsveta, perhaps you could begin with that, and I believe you put it the right way regarding extending further into the broader reach within the NTD population. Tsveta, do you want to handle that, and then we'll address gross to net separately?
Tsveta Milanova
executiveSure. I'm quite happy with how things are going up to this point. We're genuinely observing a strong beginning to this launch, in terms of both getting into the community practice, where most prescribers sit, and getting into the NTD setting, which represents the larger commercial chance. During the second quarter, as we said, we picked up 200 prescriptions from physicians certified through REMS. Once we get into the back half of the year, growth in prescriptions and growth in revenue won't line up in a perfectly direct way, since the launch is entering a more mature stage. Revenue also hinges on how long it takes for treatment to begin, REMS onboarding, and persistency, all of which we've talked about. Looking forward, when we shift into the NTDT setting, we anticipate the time until treatment starts stretching well into 10 to 12 weeks, because these patients see healthcare professionals less often, and they'll also have to complete insurance verification along with the REMS process. We're truly, truly heartened by how quickly patients are adopting this, the strides we're making, the manner in which patients convert and remain on therapy at this stage of the launch, and above all, the genuinely favorable comments I keep hearing from clinicians about the product profile as it performs in the real world.
Brian Goff
executiveThanks. Supath, regarding the latter portion of what you asked, I believe it concerned the 10%-20% guidance we provided on gross to net. Cecilia, would you like to say something about that?
Cecilia Jones
executiveOur expectation is that this will stay within the 10%-20% band we've previously provided guidance on. Quarter-over-quarter, you'll always see some fluctuation, yet when taken as a whole, we continue to anticipate that same range.
Marc Frahm
analystHello. I appreciate you fielding my questions. I fully understand the forces affecting conversion of a TRx to real revenue; naturally, some patient attrition will occur at the far end beginning in the latter half. Do you see those 200 patients near the top of the funnel as a level that can now be maintained, or does that figure still carry some of the bolus you referenced regarding Q1's backlog of REMS certifications along with those extremely motivated patients?
Brian Goff
executiveYes. Perhaps I'll begin, then hand things to Tsveta. Marc, I believe a useful frame for something we've said on multiple occasions regarding engaged patients and engaged clinicians is that it forms a gradient; we recognize we remain at the early portion of it. Tsveta also just spoke to this. As we progress deeper into the NTD population, inherently these patients generally experience fewer clinical interactions. That's basically the situation we face. Tsveta, anything you'd like to add?
Tsveta Milanova
executiveRight. No, definitely. Like I said during my prepared comments too, as we look toward a new launch phase beginning in the second quarter, we anticipate that prescription growth and revenue growth won't line up one-to-one each quarter, given how long it takes for treatment to start, the rate at which patients convert and stay on therapy, and ordering swings between quarters. So after the third quarter, we're actually going to shift away from using prescriptions as that early demand signal, and instead point to something we feel better captures the fundamental health of the business, and that's revenue. If you consider how the first half will bridge into the launch's next stage, meaning the second half; during the first half, in Q1 and partly in Q2, we truly gained from those early adopter, highly motivated patients and physicians, the PDUFA delay, which built up anticipation for the launch, and patients and physicians eager to begin as fast as they could. Once we get into the launch's second part, what I'm watching for is really the launch's underlying dynamics, which let us push further into the community setting, achieve very strong adoption in the NTDT setting among alpha and beta thalassemia patients, and settle into that steadier state of 10 to 12 weeks for treatment initiation; we feel very encouraged by how the launch is progressing and by how the team is executing.
Marc Frahm
analystAll right, that's useful. Turning to the opposite side of the funnel — the rate at which people stop treatment — do you think the earliest patients, those extremely driven individuals and doctors who began therapy during Q1 and the early part of Q2, are more inclined to remain on the drug thanks to that drive? Or could they instead be the especially difficult-to-treat cases, meaning their discontinuation rate might come in somewhat above whatever the longer-term figure turns out to be?
Tsveta Milanova
executiveOnce we move further into the next stage of the launch, we'll share additional detail about what shows up in the real world. What I'd propose right now, and what clinicians are telling us, is that the main period from the clinical trials serves as a strong stand-in for continuation, and we'll keep gaining more insight. The payer policies already issued make me quite happy. They genuinely give patients and physicians considerable room to make well-informed decisions about continuing treatment. Those policies truly aim at managing patients toward clinical trial criteria or beyond. For the moment, let's treat the clinical trial as that stand-in.
Marc Frahm
analystOkay. Thanks.
Brian Goff
executiveThanks, Marc.
Samantha Semenkow
analystHello, and good morning. I appreciate you taking my question, and please let me include my congratulations regarding the impressive quarter. I'd like to know whether you might elaborate a bit further on what happens with the clinical evaluation following 6 months of treatment, which you mentioned during your prepared remarks. When it comes to deciding whether to keep a patient on treatment, what do physicians consider an acceptable clinical bar? Regarding this 6-month clinical milestone, is it quite rigid, or does some latitude exist such that the timing could shift for when a physician would want to evaluate how a patient is progressing clinically? I have one more question after this.
Brian Goff
executiveThank you, Sam. This one is also well suited to Tsveta, particularly since we already possess significant learnings from our experience with PKD, spanning many years now when it comes to evaluation.
Tsveta Milanova
executiveCertainly. How patients and physicians characterize benefit varies, and I'll say benefit since frequently it extends past whatever gets designated as the primary endpoint in trials. Naturally, when it comes to transfusion-dependent individuals, patients alongside physicians examine decreases in transfusions, considering the capacity to stretch out the interval separating transfusions and also lowering the volume of blood transfused — each of these elements matters. According to what physicians tell us — and I recently had the chance to sit down with patients as well as physicians at the Polycythemia Foundation meeting — this truly gets done case by case. Most of them brought up 6 months, partly because our clinical trials fell inside that window, yet it also represents a natural moment for assessing early benefits; choices get made on that foundation. For TDT patients, lowering transfusions will matter. They won't necessarily adhere to the 50% reduction that was set out in the clinical study. It will hinge on each individual patient and whether they wish to stay on therapy too, and how they feel in the intervals between transfusions also counts. Within NTDT settings, they will examine hemoglobin improvement. One gram per deciliter isn't a strict yes or no. They will additionally consider gains in hemolytic parameters, and crucially in the NTDT context, how patients feel matters. Lessening fatigue serves as a major factor for both patients and physicians in deciding to remain on therapy regardless of the actual degree of hemoglobin improvement; we feel quite encouraged by what our customers tell us and anticipate finding out more during the second half of the year.
Samantha Semenkow
analystExcellent. Many thanks. Next, a follow-up regarding how the prescriber base is developing. Do you observe doctors prescribing for several individuals under their care? I'd like to know whether there's some kind of pattern you could describe that has emerged during the launch's initial 2 quarters. Thanks a lot.
Tsveta Milanova
executiveOf course. Looking at the prescribers we have, what matters most to me is the breadth of prescribing, since most leukemia patients receive care in the community, and we lack extensive breadth throughout the therapy area. I'm seeing quite robust prescribing breadth nationwide, coming from a range of clinicians. The launch's healthy beginning makes me quite happy; a limited group of key opinion leaders has prescribed for more than 1 patient, and prescriptions from these writers keep arriving; we anticipate that will persist. Their patient base is stable. Truly, our chance lies in further penetrating the community setting.
Samantha Semenkow
analystThanks very much.
Brian Goff
executiveThank you.
Eric Schmidt
analystThank you, Mike. Congratulations on everything that's been accomplished, and sadly I've got one more question for Tsveta. She really appears to be in the hot seat right now. I'd simply like clarity regarding what those 442 cumulative prescriptions you're reporting actually contain. In the past, I believe you stated that these correspond to individual patients tied to individual start forms and would not cover refills or similar items. Does that remain true?
Tsveta Milanova
executiveWithout a doubt. These represent unique patient prescriptions. In some sense, that is essentially the same thing as a start form, and a REMS-certified physician writes it.
Eric Schmidt
analystI'm guessing, Tsveta, that you also have some visibility into the number of refills written so far?
Tsveta Milanova
executiveYes, refill rates are holding steady as patients get to month two and month three of treatment. Things with refills are going along as we expected. Refills keep arriving based on which patients have begun and are making their way through the REMS. What we aren't giving out is any particular picture of refill patterns and how many patients in total are on therapy. Like I mentioned, going forward, our emphasis will shift away from start forms and toward revenue instead, since that captures every one of these dynamics you're asking about, Eric. Patients newly starting, the time it takes to begin treatment, refills, and staying on therapy.
Eric Schmidt
analystYou covered everything I was going to ask. Just one thing remains for me — how patients move from START forms over to actually receiving therapy. Can you tell whether a significant number, or even any at all, have left the waiting pool while they're waiting for treatment? Thanks.
Tsveta Milanova
executiveOur payer policies are quite favorable, and no obstacles to market access exist on our end. At this early stage of the launch, that makes me very happy. The rate at which prescriptions get filled — meaning scripts turning into patients who begin therapy — is extremely high, and it aligns closely with what we see in other rare diseases. There's nothing unexpected in that. That very strong conversion rate pleases me a great deal.
Brian Goff
executiveEric, one more point from me on that: this is another spot where what we learned with PKD — on a smaller scale, sure — genuinely matters, since what tends to be the issue when a START form turns into a patient beginning therapy is timing rather than a loss. And once again, with these NTDT patients, the further we push into that penetration, the more time it may require, so from where you sit, the translational step between a START form and revenue only grows tougher and tougher.
Eric Schmidt
analystGreat. Thanks. Congrats again.
Brian Goff
executiveThanks a lot.
Emily Bodnar
analystMorning, and thanks for taking my question. Appreciate it, and congratulations on the strong quarter as well. On the thalassemia sales in Europe — did any portion of the 2Q revenues come specifically from Europe? And how are you thinking about revenue growth outside the U.S. for the rest of the year? Then maybe second, given the sickle cell disease PDUFA in November, do you expect a launch before the year ends, and should we anticipate any initial revenues in the fourth quarter? Thank you.
Brian Goff
executiveThank you, Emily. Cecilia can address the European question, and then we can return to the sickle cell one.
Cecilia Jones
executiveRight. Emily, when it comes to revenue outside America up to this point in the quarter, two things are driving it: steady, ongoing demand in the GCC, where we already have early access, plus expected demand for Thalassemia in Europe now that approval came through in May. I would say that for the quarters ahead, we still look for the bulk of our revenue to come from the U.S., since we're continuing to build up those other regions — early access on both fronts. Neither one, in our view, will be a meaningful contributor. Then there's the other question, about sickle. Once again, with the PDUFA date set for November, it wouldn't add anything material to our revenues for the full year 2026.
Brian Goff
executiveLet me just jump in here, Emily, and say that we're excited about the chance for a priority review, along with a PDUFA date of November 1st, in sickle cell. You all probably aren't aware of this, but right now we happen to be attending a fairly significant gathering of sickle cell KOLs and community physicians. I mention that because I feel a great deal of pride in what Tsveta and the team are accomplishing to prepare for that launch, and we are definitely aiming to leverage as much as possible from the strides we're making in Thalassemia toward that launch too.
Emily Bodnar
analystThank you.
Brian Goff
executiveThank you.
Analyst
analystMorning, everyone. Lydia here, filling in for Salveen. We really appreciate you taking the time for our question, and nice work on the progress. Would you be able to give us a broad picture of where things currently stand in terms of the split between transfusion-dependent and non-transfusion-dependent patients, and at what point do you think the non-transfusion group will account for most of the people on treatment? And then, just quickly following up on that, when you get to that 10 to 12-week range, is that the rate you'd expect to continue going forward? Thanks a lot.
Brian Goff
executiveAbsolutely, Lydia. Tsveta?
Tsveta Milanova
executiveSure. What we're observing at this point is that the NTDT portion keeps expanding, which is exactly what we've stated all along and what we had expected. During the first quarter, and to some extent the second quarter, a sizable share of the patients were TDT patients, since those individuals interact with the healthcare system more often and generally belong to the more engaged group of patients. In the second quarter, we've witnessed considerable growth among NTD patients. We anticipate that this will keep going. When you examine how our initial launch focus breaks down, roughly 4,000 patients are the ones we're targeting at the outset, and approximately 50% of that group are NTD patients. We'll keep penetrating that segment; we expect the 10 to 12-week average time to treatment initiations to stabilize and stay constant going forward.
Tessa Romero
analystHello, Brian, and hello to everyone on the team. We appreciate you fielding our question. Just as a brief bit of housekeeping, could you remind us how we ought to properly frame the LOE for mitapivat? Then, to dig a little deeper, how should we correctly think about the way cumulative scripts for AQVESME are likely to move between the close of 2Q and the close of 3Q? At what point might you be ready to provide revenue guidance if script counts stop being disclosed once 3Q is over? Thank you.
Brian Goff
executiveThanks, Tess. The first part is easy. For mitapivat, the LOE can be viewed as 2035, covering composition of matter along with extensions. Beyond that, there's further possibility for patent extensions. On the second point, naturally, where things stand as we move from 2Q into 3Q, that will be directional. No specific guidance is being offered by us, but in qualitative terms, Tsveta, my sense is this will resemble what you've said previously regarding additional penetration.
Tsveta Milanova
executiveCertainly. When we think about the back portion of this year, we expect to keep making inroads within the NTDT segment. Those individuals, as we're aware, come to see their healthcare providers on a less frequent basis. Given that, we also expect the timeline for starting treatment to fall somewhere between 10 and 12 weeks, and that will be a major factor shaping the quarter. In addition, we've now arrived at the significant six-month milestone for assessing treatment benefit, which is among the primary reasons we'll begin shifting past Q3 toward generating revenue instead of a steady stream of prescriptions. Of real importance, we have a notable date coming up, November 1st, when we add the sickle cell disease launch. Assuming that launch goes as we hope, we'll share additional details on how we can describe the trajectory of the mitapivat franchise across indications. That will happen once the launch occurs.
Brian Goff
executiveCecilia, Tess managed to squeeze in one more inquiry regarding guidance and its timing, so would you like to say something about that?
Cecilia Jones
executiveRight. Tess, as Tsveta pointed out, with sickle cell also joining once approval potentially arrives in November, we'll figure out when the right moment is to give guidance on the franchise moving ahead.
Brian Goff
executiveGood. Thank you.
Tsveta Milanova
executiveThank you.
Analyst
analystHello, everyone. Shelby here, filling in for Luca — appreciate you fielding our question. Turning to the commercial groundwork for a possible sickle cell launch: my understanding is that this indication carries a larger Medicaid share than thalassemia and PKU. First, is that accurate? Second, what's your view on gross-to-net and net revenue per patient in sickle cell compared with your other products already on the market? And does the Novo competitive situation play any role in how you set price? Any insight would be great.
Tsveta Milanova
executiveOf course; we will certainly share further detail on pricing once approval comes, and that will depend on the label as well as the competitive landscape at that point, and we'll keep watching how it evolves. Naturally, the sickle cell disease population includes a greater Medicaid proportion, and that inherently carries a mandatory rebate of 23%, which pushes gross to net higher than is the case for PKU and thalassemia. I can say we're extremely thrilled about the PDUFA date, and the team stands ready to launch.
Brian Goff
executiveOkay, thank you all for the questions and for being with us today. Tsveta took the hot seat this time, and we quite enjoy that — many thanks for it. In closing, we feel very good about what we achieved during the second quarter. That covers keeping up the launch momentum for AQVESME, moving mitapivat ahead toward a possible approval in sickle cell disease, as we just went through, bolstering our pipeline through cevidoplenib and AG-236, and preserving the financial flexibility needed to execute. In the end, we head into the year's second half with focus, discipline, and confidence in our capacity to create long-term value for patients as well as shareholders. Many thanks, and we look forward to talking with all of you before long.
Operator
operatorEveryone, that brings us to the end of this conference call. We appreciate all of you joining in. At this point, you're free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.